JH-021

Primary Objectives: Phase Ia: Dose Elevation Study To evaluate the safety and tolerability of JH021 in patients with advanced solid tumors; to determine the maximum tolerated dose (MTD) of JH021 (if applicable), and to determine the clinically recommended dose. Phase Ib: Dose Expansion Study To evaluate the efficacy of JH021 monotherapy in patients with EGFR-mutant, third-generation EGFR-TKI-resistant, and platinum-based chemotherapy-advanced (or untreated) locally advanced or metastatic NSCLC. Secondary Objectives: Phase Ia: Dose Elevation Study To evaluate the pharmacokinetic characteristics of JH021 in subjects with advanced solid tumors. To evaluate the immunogenicity of JH021 in subjects with advanced solid tumors. To evaluate the preliminary efficacy of JH021 in subjects with advanced solid tumors. Phase Ib: Dose Expansion Study. To evaluate the safety, pharmacokinetic profile, and immunogenicity of JH021 in patients with EGFR-mutant, third-generation EGFR-TKI-resistant, and platinum-based chemotherapy-treated (or without standard treatment) locally advanced or metastatic NSCLC. Exploratory Objective: To investigate the relationship between EGFR mutation type or MET amplification or expression and the antitumor efficacy of JH021.